Get the Stockscreener App
1.02
6.42%
-0.07
After Hours:
1.02
Oncolytics Biotech Inc stock is traded at $1.02, with a volume of 2.36M.
It is down -6.42% in the last 24 hours and up +35.89% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$1.09
Open:
$1.08
24h Volume:
2.36M
Relative Volume:
2.17
Market Cap:
$96.17M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-3.8563
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
-17.74%
1M Performance:
+35.89%
6M Performance:
+40.11%
1Y Performance:
-2.95%
1-Day Range:
$1.00
$1.11
1-Week Range:
$1.00
$1.2091
52-Week Range:
$0.3258
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.02 | 105.30M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments - PR Newswire
What’s the recovery path for long term holders of Oncolytics Biotech Inc.High Conviction Intraday Stock Signals Detected - metal.it
Survival Data and Regulatory Greenlights Fuel Momentum in Immunotherapy Stocks - Baystreet.ca
Oncolytics Biotech to engage FDA on potential pancreatic cancer study - Investing.com Australia
Oncolytics Biotech sparks FDA discussions for potential pivotal pancreatic cancer trial | 2025-07-29 | Investing News - Stockhouse
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech Inc - Baystreet.ca
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Engages FDA for Pivotal Pancreatic Cancer Study - TipRanks
Published on: 2025-07-29 15:02:09 - metal.it
Oncolytics Biotech's Strategic FDA Engagement: A Catalyst for Market Redefinition in Pancreatic Cancer - AInvest
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End - Barchart.com
What makes Oncolytics Biotech Inc. stock price move sharplyAI Forecast for Trending Stocks Indicates Upside - metal.it
What are the latest earnings results for Oncolytics Biotech Inc.Maximize returns with smart investment plans - jammulinksnews.com
What catalysts could drive Oncolytics Biotech Inc. stock higher in 2025Discover hidden gems in the stock market - jammulinksnews.com
What institutional investors are buying Oncolytics Biotech Inc. stockInvest confidently with professional market insights - jammulinksnews.com
Why is Oncolytics Biotech Inc. stock attracting strong analyst attentionReal-time trading signals for maximum returns - jammulinksnews.com
How many analysts rate Oncolytics Biotech Inc. as a “Buy”Build a portfolio that outperforms consistently - jammulinksnews.com
What is the dividend policy of Oncolytics Biotech Inc. stockGet real-time updates on market trends - jammulinksnews.com
Is it the right time to buy Oncolytics Biotech Inc. stockBuild a portfolio that outperforms consistently - jammulinksnews.com
H.C. Wainwright Analyst Reiterates Buy Rating on Oncolytics Biotech with $5 Price Target - AInvest
Buy Rating for Oncolytics Biotech Driven by Promising Pelareorep Data in Pancreatic and Colorectal Cancers - TipRanks
What drives Oncolytics Biotech Inc. stock priceSuperior trading gains - PrintWeekIndia
Is Oncolytics Biotech Inc. a good long term investmentRecord-breaking capital gains - PrintWeekIndia
Oncolytics Biotech Inc. Stock Analysis and ForecastConsistently high yield - Autocar Professional
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules - Eastern Progress
(ONC) Technical Analysis and Trading Signals (ONC:CA) - news.stocktradersdaily.com
What analysts say about Oncolytics Biotech Inc. stockFree Stock Market Real-Time Monitoring - jammulinksnews.com
Oncolytics Biotech Regains Nasdaq Compliance as of July 22, 2025 - The Globe and Mail
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve
Oncolytics Biotech Highlights Pelareorep’s Potential in Pancreatic Cancer at KOL Event - TipRanks
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential – Company AnnouncementFT.com - Financial Times
Cancer Surge Meets Funding Crunch as Breakthrough Biotechs Line Up Milestones in 2025 - Baystreet.ca
Pancreas Cancer Becoming Top Focus for Biotech Co.? - streetwisereports.com
Oncolytics Biotech Regains Compliance With Nasdaq's Minimum Bid Price Rule - 富途牛牛
Oncolytics Biotech regains compliance with Nasdaq listing requirements - Investing.com
Oncolytics Biotech regains compliance with Nasdaq listing requirements By Investing.com - Investing.com South Africa
Oncolytics regains Nasdaq compliance - TipRanks
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
10.28%
2.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):